Dermatology & Skin Care Hyderabad

Every month brings a skin and hair treatment update from somewhere in the world — a new treatment gets approved, a study changes what doctors recommend, or a popular belief gets quietly disproved. Most of it never reaches patients in plain language. So here is our simple, jargon-light roundup of the skin and hair treatment news that actually mattered in July 2026, and what it means for you. No hype, no miracle cures — just the developments worth knowing about, explained by the dermatology team at Rida Radiance in Gachibowli, Hyderabad. In This Month’s Skin and Hair Treatment Update 1. A New Type of Anti-Wrinkle Injection That Wears Off in 2 to 3 Weeks This was the month’s biggest headline. Europe approved a brand-new anti-wrinkle injectable called Boey (trenibotulinumtoxinE) for frown lines. Canada approved it in June. What makes it different? Regular Botox-type anti-wrinkle treatments take a few days to kick in and last three to four months. This one can start working within about 8 hours — and wears off in roughly two to three weeks. Why you might care: the most common worry we hear from first-timers is “what if I don’t like how I look?” A short-acting option turns that from a three-month commitment into a two-week try-out. Think of it as a test drive before deciding whether injectables are for you. It is not available in India yet. But it signals where the industry is heading: lower-commitment, more reversible treatments. And an important safety warning In the same month, the UK’s medicines regulator (MHRA) issued a warning about rare but serious complications from botulinum toxin injections, where the product spreads beyond the injection site. Patient leaflets are being updated. The regulator was blunt about the real problem: fake and unlicensed toxin products sold outside proper supply chains, and injections given at unapproved sites or in unusually high doses. What to do about it: before any injectable treatment, ask two questions — which licensed brand is being used, and what are the qualifications of the person injecting it? A clinic that answers both easily is a clinic worth trusting. Bargain pricing on injectables is almost always a warning sign, not a deal. 2. Hair Loss Research: The Biggest Skin and Hair Treatment Update of the Month Three separate developments, all pointing in encouraging directions. This was easily the most significant part of July’s skin and hair treatment update. A properly tested oral minoxidil for women Low-dose minoxidil tablets have been prescribed off-label for years alongside in-clinic options such as PRP hair treatment and GFC therapy, including in India, without a purpose-built version ever being formally studied and approved. That is now changing. A phase 2 study of an extended-release oral minoxidil (VDPHL01) in women with mild-to-moderate pattern hair loss reported an increase of more than 22 hairs per square centimetre at six months, and close to 90% of women said they saw improvement themselves. Why it matters: female pattern hair loss has long been under-served compared with male hair loss. Solid data in women specifically is genuinely useful, and it complements existing options such as hair mesotherapy and, in advanced cases, hair transplant surgery. New hope for patchy hair loss when current drugs fail For alopecia areata — the autoimmune condition that causes sudden patchy or complete hair loss — a new antibody treatment called bempikibart showed positive 36-week results in severe cases. Around 40% of patients regained roughly 80% scalp coverage. The most meaningful detail: over a third of the patients had already tried JAK inhibitor tablets, the current best option. Right now, people who don’t respond to those have very little left to try. An injection you might only need 2 or 3 times a year An early-stage trial tested ABS-201, an experimental antibody for common male and female pattern baldness. It works through a completely different pathway from minoxidil or finasteride, and it was well tolerated in 32 healthy volunteers, with mild headaches the main side effect. The exciting part is how long it stays in the body — possibly just two or three injections over six months. Why that is a big deal: the biggest reason hair treatments fail is not that they don’t work. It is that people stop applying or taking them daily. A few injections a year would solve that. An important reality check on all three: these are research-stage treatments. None of them can be prescribed today, anywhere. Realistically we are looking at 2027 and beyond, and Indian approval would come later still. One that is genuinely close Europe’s medicines committee recommended approving upadacitinib (an existing tablet already used for eczema and arthritis) for severe alopecia areata in adults and teenagers. Final European approval is expected within months, and the US FDA is reviewing it too. This one is close to real-world availability. 3. Lasers May Do More Than Smooth Your Skin Here is the most fascinating study of the month. Researchers treated one side of the face of 22 adults with a non-ablative fractional laser, three sessions a month apart, and followed them for six months. They then examined the skin at a molecular level — over 3.8 million genetic markers per sample. The laser appeared to shift patterns linked to how skin ages at the level of gene activity, not just how it looks on the surface. In plain English: laser resurfacing may be nudging some of the underlying biology of ageing skin, not merely resurfacing it. This is early, small-scale research and nobody should be promising “age reversal” from it — which is exactly why our longevity and anti-ageing plans are built on established treatments rather than headlines. But it is a serious hint that these treatments do more than we assumed. 4. Good News If You Have Melasma and Deeper Skin Tone Melasma — those stubborn brown or grey-brown patches, usually on the cheeks, forehead and upper lip — is one of the hardest skin conditions to treat, especially in Indian and other deeper